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Malignant hyperthermia (MH) is a potentially fatal
autosomal dominant disorder of skeletal muscle and
is triggered in susceptible people by all commonly used
inhalational anaesthetics and depolarizing muscle
relaxants. To date, six mutations in the skeletal muscle
ryanodine receptor gene (RYR1) have been identified
in malignant hyperthermia susceptible (MHS) and
central core disease (CCD) cases. Using SSCP analysis,
we have screened the RYR1 gene in affected
individuals for novel MHS mutations and have identified
a G to A transition mutation which results in the
replacement of a conserved Gly at position 2433 with
an Arg. The Gly2433Arg mutation was present in four
of 104 unrelated MHS individuals investigated and was
not detected in a normal population sample. This
mutation is adjacent to the previously identified
Arg2434His mutation reported in a CCD/MH family and
indicates that there may be a second region in the
RYR1 gene where MHS/CCD mutations cluster.
INTRODUCTION
Malignant hyperthermia (MH) is an autosomal dominant disorder
of skeletal muscle and is one of the main causes of death due
to anaesthesia. In susceptible people, an MH episode can be
triggered by all commonly used inhalational anaesthetics such
as halothane and by depolarizing muscle relaxants such as
succinylcholine. The clinical features of the myopathy are
hyperthermia, accelerated muscle metabolism, contractures,
metabolic acidosis and tachycardia (reviewed in 1).
Susceptibility to MH (MHS) is predicted by observing the
magnitude of contractures induced in strips of muscle tissue in
vitro by caffeine alone and halothane alone (2,3). This test is
called the in vitro contracture test (TVCT). Patients who exhibit
a normal response are diagnosed as MH normal (MHN) while
those with an abnormal response to both caffeine and halothane
are diagnosed as MH susceptible (MHS). Patients exhibiting an
abnormal response to caffeine alone or halothane alone are
diagnosed as MH equivocal (MHE(c) and MHE(h) respectively)
(3).
Molecular genetic studies have shown that the MHS locus maps
to the RYR1 region of human chromosome 19q in many cases
(4,5) and to date, six RYR1 mutations have been reported in MHS
and central core disease (CCD) pedigrees. CCD is a rare inherited
myopathy closely associated with MHS (6,7).
The first reported RYR1 mutation resulted in an Arg to Cys
substitution at position 614 and has been found in 3—5% of
human MH families investigated (8). This mutation was also
shown to be present in all cases of swine affected with MH (9).
Recently, we reported a Gly to Arg substitution at position 341
which accounts for approximately 10% of MHS cases investigated
(10) and an Argl63Cys mutation (11) which accounts for 2 - 3 %
of MHS cases and a CCD case. The mutations Gly248Arg,
De403Met and Arg2434His have also been reported in the RYR1
gene in three independent MHS and/or CCD pedigrees and
appear to be private mutations (11-13).
Genetic heterogeneity has been reported in MH (14,15) and
a second MHS locus has been tentatively localized to the
ql 1.2—q24 region of chromosome 17 in North American
pedigrees (16). Recent linkage studies in European MHS
pedigrees support the existence of genetic heterogeneity but have
excluded the possibility of a second MHS locus mapping to
17qll.2-q24 (17,18).
In an effort to identify new mutations in the RYR1 gene causing
MH we have undertaken the systematic screening of the 15.5
kb RYR1 gene in unrelated MHS individuals for mutations. We
describe here the identification of a novel Gly2433Arg mutation
which we detected in four unrelated MHS pedigrees.
RESULTS
SSCP analysis of the RYR1 gene in MH
For mutation analysis, cDNA was synthesized from total RNA
isolated from skeletal muscle biopsy samples from 21 unrelated
MHS patients. The previously reported MHS mutations were not
detected in these samples (data not shown). Screening for single
nucleotide changes in polymerase chain reaction (PCR) amplified
RYR1 segments from the MHS patients was performed using
the single-stranded conformation polymorphism (SSCP) method
(19). PCR primers were designed so that the 15.5 kb coding
sequence of the RYR1 gene (20) could be amplified in short
(250-450 bp) overlapping segments. Aberrant SSCP patterns
were detected in different areas of the RYR1 gene in 21 MHS
patients. The majority of the SSCPs detected in these segments
reflected commonly occurring polymorphisms (12). However,
of the SSCPs detected, an aberrant pattern was present in RYR1
segment 6995-7393 (Figure 1) in patient HJ-3 of pedigree A
(Figure 2) and direct sequencing showed the presence of the single
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Figure 1. Autoradiograph of SSCPs detected in RYRl segment 6995-7393 in
normal controls 0anes 1, 2), and seven unrelated MHS individuals (lanes 3-9) .
Lane 9 is from individual IH-3 of pedigree A. PCR was carried out with primers
6995 (5'-ACTTCCTGCGCTTTGCTGTCT-3') and 7393 (5'-GAGGCTGATG-
ATGCCCACAAG-3') and at an annealing temperature of 57°C as previously
described (11).
base substitution G7297A which results in the replacement of
a Gly with an Arg at position 2433 (Figure 3). The complete
RYRl gene in patient HI-3 was investigated by SSCP analysis
under three different electrophoretic conditions alongside control
MHN samples and MHS samples known to bear the previously
characterized Arg614Cys (21) or Gly341Arg (10) mutations. In
addition to the SSCP in segment 6995-7393, SSCPs were
detected in nine different segments of the RYRl gene from patient
DI-3. The nine SSCPs were considered innocuous polymorphisms
as they were present in some of the control samples and/or were
shown to be due to previously reported polymorphisms by
restriction enzyme analysis (12).
As the G7297A mutation creates AlwNl and Ddel restriction
sites, either of these enzymes can be employed to check for the
presence of the mutations in amplified RYRl segments. In order
to check for the presence of the G7297A missense mutation in
the multi-exon RYRl gene (8) in genomic DNA samples, it was
necessary to design PCR primers that would allow amplification
of the mutated region from genomic DNA. Using the primers
7270 and 7301 (see Materials and Methods), it was possible to
amplify a 55 bp genomic fragment encompassing the G7297A
mutation. The amplified fragment was the same size as anticipated
from the cDNA sequence and the presence of the mutation was
verified by selective cleavage with the restriction enzyme A /wNI
(Figure 4).
To establish whether the Gly2433Arg missense mutation was
present in the normal population, 200 normal chromosomes were
examined for the presence of the mutation. None displayed the
candidate mutation. In order to determine whether this mutation
was present in the RYRl gene of other MHS pedigrees and/or
CCD pedigrees, 83 additional unrelated MHS and four unrelated
CCD patients were investigated for the presence of the mutation.
The mutation was detected in one Irish and two German MHS
patients (individuals HI-8, IV-1 and IH-1 of pedigrees B, C and
D, respectively).
Segregation analysis of the Gly2433Arg mutation was
performed in the families of individuals displaying the mutation
and showed that the mutation co-segregated with the MHS
phenotype in each family with the exception of one individual,
namely individual m-5 of pedigree A (Figure 2).
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Figure 2. Segregation of the RYRl G7297A mutation in four MH pedigrees.
+ indicates the presence of the mutant allele, - indicates the presence of the
normal allele. "Family A was tested by the caffeine contracture test prior to the
introduction of the standardized European IVCT protocol (3) in 1984. Family
B, C and D were tested by the standardized European FVCT protocol.
DISCUSSION
In an effort to identify new mutations in the RYRl gene causing
MHS, we have investigated the RYRl gene in unrelated MHS
patients for the presence of new mutations by the SSCP method
and have detected a novel Gly2433Arg mutation in four of 104
unrelated Caucasian MHS patients. The Gly2433Arg mutation
segregates with MHS in the pedigrees investigated with the
exception of individual III-5 of pedigree A. The MHS diagnosis
of the individuals in family A by the IVCT was performed in
1982, prior to the introduction of the standardized IVCT protocol
(3). At this time, a patient was diagnosed as MHS if muscle
biopsy strips produced a sustained increase of 0.2 g baseline
tension at a caffeine concentration of 2 mM or less. The result
of the contracture test on individual HI-5 was 0.64 g at 2 mM
caffeine and therefore, individual EH-5 was diagnosed as MHS.
Since the introduction of the standardized IVCT protocol, MHS
diagnosis requires that the patient exhibits a positive response
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Figure 3. Nucleotide and deduced amino acid sequences of the region of the
RYR1 gene bearing the G7297A mutation. The alteration of the normal sequence
CTCGGNNNCTG starting at nucleotide 7294 to the mutant sequence CTCAG-
NNNCTG creates an /1/wNI and a Ddel site in the mutant sequence.
Figure 5. Amino acid sequence of the regions of the RYR1 protein and related
isoforms flanking the residue Gly2433. Residues identical to the human isoform
are boxed.
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Figure 4. Segregation of the G7297A mutation by restriction enzyme analysis
in members of pedigree A. Autoradiograph of the digestion products of the 55
bp PCR amplified segment encompassing the G7297A mutation with AlwNl.
Cleavage of the 55 bp mutant allele with /4/ivNI results in 27 and 28 bp products.
to caffeine and halothane independently. The Gly2433Arg
mutation segregates precisely with the MHS phenotype in the
families diagnosed by the standard FVCT. Thus, the most likely
explanation for the absence of the mutation in individual III-5
is that this individual has recorded a false positive reaction in
the IVCT. In support of this notion, it has been reported that
the North American IVCT protocol (which is largely similar to
the European protocol) achieves a sensitivity of 100% in MHS
detection. However, to achieve this sensitivity, the specificity
of the test is compromised to 78% (22). Therefore, it is reasonable
to assume that false positive diagnoses also exist using the
European protocol especially before standardization in 1984.
Furthermore, we have recently shown (10) that responses of up
to 0.9 g tension occurred in Gly341Arg negative MHE(c)
individuals within pedigrees in which the Gly341Arg mutation
was segregating precisely with the MHS phenotype (10). It is
possible that a second mutation causing MHS or contributing to
an abnormal IVCT response is present in family A. However,
the tight association between the Gly2433Arg mutation and the
MHS phenotype in the pedigrees investigated and the absence
of the mutation in 200 normal chromosomes tested argues
strongly in favour of this mutation being causative of MHS. In
addition, examination of the RYR1 genes sequenced to date (9,20)
and related cardiac (RYR2) (23) and brain (RYR3) (24) genes
indicates that Gly2433 is a functionally important amino acid in
the RYR proteins since it is conserved across species (Figure
5). To obtain conclusive proof that this is a causative mutation,
it will be necessary to investigate the effect of the Gly2433Arg
mutation on the RYR1 channel activity and/or determine its
effects in an animal model system.
Family B is unusual in that three of the four siblings were
diagnosed as MHE(h). None of these individuals had the
Gly2433Arg mutation. Examination of their contracture records
shows that they all exhibited a marginal response to halothane
which suggests that these patients may be normal from both a
genetic and clinical viewpoint. However, since about 12% of
probands are diagnosed as MHE in the IVCT (25) it is essential
to classify all MHE individuals (including those in which an
obvious MHS mutation is not segregating) as MHS until the
relationship between the MHS and MHE phenotypes becomes
much clearer.
The mutation reported here has diagnostic potential. However,
as misdiagnosis could be fatal and as the reason for the apparent
occurrence of the MHS false positive and MHE phenotypes is
currently unclear, we strongly advocate corroboration of genetic
diagnosis with the IVCT.
The detection of the Gly2433Arg mutation brings to seven the
total number of RYR 1 mutations reported to date in MHS/CCD
pedigrees. Five of the previously reported MHS/CCD mutations
cluster in the amino terminal region of the RYR1 protein whereas
the Gly2433Arg mutation is positioned adjacent to the previously
identified Arg2434His CCD mutation. Interestingly, none of the
patients with the Gly2433Arg mutation had clinical signs of CCD.
Only family B has been investigated histologically and none of
the MHS individuals in this family exibited central cores. This
indicates that the Gly2433Arg mutation is associated with a milder
phenotype than the Arg2434His mutation. The location of a
second mutation close to the Arg2434His CCD mutation indicates
that there may be a second region in the RYR1 gene where
MHS/CCD mutations cluster. The Gly2433Arg and the
Arg2434His mutations occur in a domain of the RYR 1 protein
thought to be modulated by ATP, phosphorylation and calmodulin
binding (26). It will be interesting to determine if these mutations
alter channel regulation with respect to these modulators.
MATERIALS AND METHODS
Genomic DNA was extracted from peripheral blood as described (27). Total RNA
was extracted from 100 mg muscle biopsy samples by guanidinium thiocyanate
extraction (28). First strand cDNA synthesis and PCR amplification of RYR1
gene segments was carried out using overlapping primers designed from the
published human RYR1 sequence (20), as previously described (10).
Nondenaturing gel electrophoresis for SSCP detection and direct sequencing of
PCR products was performed as previously described (10).
Segregation studies
A 55 bp fragment spanning the G7297A mutation of the RYR1 gene was amplified
from genomic DNA using PCR. The reactions were carried out in a total volume
of 10 p\, with 100 ng of genomic DNA, 20 ng of each primer 7270 (5'-TTCTA-
TGCCGCCTTGATCGACCTG-3')and 7301 (5'-TTAGATGCATCTCTGGT-
GCACAGC-3'), 0.2 mM of each dNTP, 50 mM KCI, 10 mM Tris-HCL, pH
9.0 at 25°C, 0.1% Triton X-100, 1.5 mM MgCl2 and 0.5 U of Taq polymerase
(Promega) and 2 iiC\ of o^P dCTP (3000 Ci/mmol). A thermal profile of 94°C
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for 5 rain followed by 94°C for 1 min, 51°C for 1 min and 72°C for 1 min
for 30 cycles and then 72°C for 10 min was performed. A 1 y\ aliquot of the
amplified 55 bp genomic fragment was then cleaved with AlwNl in a reaction
volume of 10 /d. The G7297A mutation results in the creation of the /f/tvNI site,
producing 27 and 28 bp digestion fragments. Digestion products were resolved
by electrophoresis through 20% polyacrylamide gels and visualized by
autoradiography.
Patients
For the investigations reported here, muscle samples were obtained from 21 MHS
patients and five MHN through the Cork, Basel and Wurzburg MH testing centres.
The patients in pedigree A were tested for MH susceptibility prior to 1984 using
an IVCT caffeine protocol similar to the standardized European Malignant
Hyperthermia Group protocol (3) established in 1984. All other patients were
investigated post-1984 using the standardized protocol. The probands in each
pedigree are pedigree A: m-14; pedigree B: m-3; pedigree C: IV-1; and pedigree
D: m-1. Each proband suffered an MH episode during anaesthesia and recovered.
Three individuals in pedigree B were diagnosed as MHE(h). The contracture data
for the MHE patients were as follows: 0.35 g at 2% halothane for individual
m-4; 0.2 g at 2% halothane for individual IH-6; and 0.31 g at 2% halothane
for individual III-7.
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